3-ketosteroid-Ξ”1-dehydrogenase (gene kstD1) from Arthrobacter simplex 156

Enzyme Description

Extremophile
No
EC Number

Sequence

Length: 515 amino acids
MDWAEEYDVLVAGSGAGGMAGTYTAAREGLSVCLVEAGDKFGGTTAYSGGGGAWFPANPVLLRAGTDDTIEDALEYYRAVVGDRTPADLQETYVRGGAGLVAYLEEDDHFSFESYPWPDYFGDAPKARRDGQRHIIPTPLPVPSAPELREVVRGPLDNDRLGTPQPDDLFIGGRALVARFLTALATYPHATLVRETALAELVVEDGVVVGAIVETDGVRRAIRARRGVLLAAGGFEANDELRQKYGVPGVARDTMGPPTNVGAAHQAAIAVGADTDLMGEAWWSPGLTHPDGRSAFALWFTGGIFVDGAGRRFVNESAPYDRLGRAVIDHLTEGGVTPRYWMVYDHKEGSIPPVRATNVSMVDEEQYVAAGLWHTADTLPELAALIGVPADALVATVARFNELVADGYDADFGRGGEAYDRFFSGGEPPLVSIDEGPFHAAAFGISDLGTKGGLRTDTSARVLTADGTPIGGLYAAGNTMAAPSGTTYPGGGNPIGTSMLFSHLAVRHMGTEDAR
Shuhong Mao et al. (2018) β€” Engineering of 3-ketosteroid-βˆ†1-dehydrogenase based site-directed saturation mutagenesis for efficient biotransformation of steroidal substrates
Microbial Cell Factories  Β· doi:10.1186/s12934-018-0981-0 β†—  Β· Activity - Classical Stability - Incubation
32 measurements
Database ID
UniProt: P77815 β†—
Sequence Annotation
Explicit - Provided GenBank Accession Number
Protein Source
Recombinant, host bacterium Escherichia coli BL21 (DE3)

Experimental Data (32 measurements)

32 measurements β€” page 1 of 2
Property Assay Solvent Solvent Volume Aqueous Reference Measured Value Units Solution pH Temperature Substrate(s) Product(s) Cofactor(s) Shaking Comments
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 35% 100.0 4.4 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 30% 100.0 14.6 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 25% 100.0 23.7 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 20% 100.0 44.0 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 15% 100.0 59.5 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 10% 100.0 75.6 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 7.5% 100.0 83.6 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Activity - Classical Activity measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in the presence of organic solvent Methanol 5% 100.0 94.2 % 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol 7.5 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Classical aqueous control (in %) | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethylformamide (DMF) 10% 100.0 131.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Acetone 50% 100.0 60.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Acetone 30% 100.0 122.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Acetone 20% 100.0 132.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Acetone 10% 100.0 126.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethylformamide (DMF) 50% 100.0 116.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethylformamide (DMF) 30% 100.0 137.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethylformamide (DMF) 20% 100.0 146.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Methanol 10% 100.0 124.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethyl Sulfoxide (DMSO) 50% 100.0 126.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethyl Sulfoxide (DMSO) 30% 100.0 148.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
Stability - Incubation Activity after incubation (2 hours at 4Β°C), measured by absorbance spectrophotometry (reduction of DCPIP to DCPIPH2, due to reduction of PMS into PMSH2 by the enzyme-FADH2, causing a decrease in absorbance, measured at 600 nm) in aqueous phase Dimethyl Sulfoxide (DMSO) 20% 100.0 169.0 % Incubation: 50 mM Tris-HCl buffer, Assay: 50 mM Tris–HCl buffer, 2% Methanol, 1.5 mM phenazine methosulphate, 40 ΞΌM 6-dichlorophenolindophenol Incubation: 8, Assay: 7.5 Incubation: 4Β°C, Assay: 30Β°C 0.5 mM Androstenedione Boldenone FAD β€” Non-incubated control (in %), assay in aqueous phase | Control with 2% methanol for subtrate solubilization
β€Ή Prev
1 2

Visualization : Activity β€” Classical

One bar per measurement. Colour = solvent, shade = solvent volume.

Visualization : Stability β€” Incubation

One bar per measurement. Colour = solvent, shade = solvent volume.

Structure

Drag to rotate Β· Scroll to zoom Β· Right-click drag to pan Β· Powered by Mol*